Bray J P, Orbell G, Cave N, Munday J S
Veterinary Teaching Hospital, Institute of Veterinary, Animal and Biomedical Sciences (IVABS), Massey University, Palmerston North 4442, New Zealand.
NZVP Laboratories, Massey University, Palmerston North 4442, New Zealand.
J Small Anim Pract. 2018 Feb;59(2):85-91. doi: 10.1111/jsap.12796. Epub 2017 Dec 6.
To investigate thalidomide as an adjuvant treatment for canine haemangiosarcoma.
Fifteen dogs with splenic haemangiosarcoma, initially treated by splenectomy, were included. Following recovery from surgery, all dogs received thalidomide continuously until their death. Tumour stage was established using CT scans of the chest and abdomen immediately before starting thalidomide treatment and again three months later. Cause of death was confirmed by post mortem examination.
The median survival time of dogs receiving thalidomide was 172 days (95% confidence interval: 93 to 250 days). Five dogs (33% of the population receiving thalidomide) survived more than 1 year (range 458 to 660 days) after surgery. Dogs with stage 2 disease that received thalidomide also had a longer survival time than dogs with stage 3 disease (median survival time 303 versus 40 days). Of 15 dogs, 13 died from metastatic haemangiosarcoma.
Treatment using thalidomide may improve survival of dogs with splenic haemangiosarcoma and should be considered a possible adjuvant therapy.
研究沙利度胺作为犬血管肉瘤辅助治疗的效果。
纳入15只患有脾血管肉瘤的犬，最初均接受脾切除术治疗。术后恢复后，所有犬持续接受沙利度胺治疗直至死亡。在开始沙利度胺治疗前及3个月后，立即对犬进行胸部和腹部CT扫描以确定肿瘤分期。通过尸检确认死亡原因。
接受沙利度胺治疗的犬的中位生存时间为172天（95%置信区间：93至250天）。5只犬（接受沙利度胺治疗群体的33%）术后存活超过1年（范围458至660天）。接受沙利度胺治疗的2期疾病犬的生存时间也比3期疾病犬更长（中位生存时间分别为303天和40天）。15只犬中，13只死于转移性血管肉瘤。
使用沙利度胺治疗可能提高患有脾血管肉瘤犬的生存率，应考虑将其作为一种可能的辅助治疗方法。
